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Introduction: Prolonged treatment with levothyroxine 4 (L-T4) is a well known
risk factor for osteoporosis. Patients on L-T4 replacement occasionally have
a subnormal TSH, which carries a risk of development of bone loss. Thyroid
hormones directly affect bone cells, stimulating osteoclastic and osteoblastic
activity with a predominance of bone resorption and decrease of bone mineral
density (BMD). 
Material and methods: The study included 35 hypothyroid patients with mean
age 11.57 ±5.06, while 26 age- and sex-matched children served as controls. Dual
energy X-ray absorptiometry (DXA) was done to detect the bone mineral density
(BMD), bone mineral content (BMC) and Z score in lumbar and femur neck
regions. Body composition was also studied by DXA. Calcium, phosphorus,
osteocalcin as a bone formation marker, osteoprotegerin as an indicator of
osteoclast activity and urinary deoxypyridinoline as a bone collagen breakdown
marker were assessed.
Results: No significant differences were detected in lumbar Z score (–0.12 ±0.66)
and femur Z score (–0.17 ±0.58) compared to controls (–0.33 ±0.74 and –0.21
±0.53 respectively). Bone mineral density and BMC were not significantly
different from controls. No significant difference was detected between cases
and controls in body composition. A positive correlation was detected between
BMD and age (r = 0.857, p < 0.01), and with the period of treatment (r = 0.766,
p < 0.01). A positive correlation was found between BMD and total body fat 
(r = 0.693, p < 0.01), and with abdominal fat (r = 0.667, p < 0.01). 
Conclusions: Levothyroxine 4 treatment in hypothyroid children does not alter
bone metabolism and body composition.
Key words: bone density, bone mineral, dual energy X-ray absorptiometry,
hypothyroid, levothyroxine 4, children.
Introduction
Hypothyroidism is mostly a permanent disease and should be treated
lifelong. Synthetic thyroxin is the preferred form of thyroid hormone
replacement therapy [1]. Hyperthyroidism causes severe osteoporosis in
children [2] but the long-term risk of osteopenia and fracture in patients
on replacement therapy for hypothyroidism is less understood [3].
Prolonged treatment with levothyroxine (L-T4) is well known as a risk
factor for osteoporosis [4, 5]. Patients on L-T4 replacement occasionally
have a subnormal TSH which carries a risk of development of bone loss
[6]. Thyroid hormones directly affect bone cells, stimulating osteoclastic
and osteoblastic activity with a predominance of bone resorption and
decrease of bone mineral density (BMD) [7, 8]. 
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Bone mass increases through childhood, with
maximal bone mass accrual occurring in early to
mid puberty and continuing, at a lower rate, in late
puberty [9, 10].
Effects of treatment with L-T4 on bone
metabolism in children have previously been
investigated and conflicting results have been
published. Demartini et al. in 2007 demonstrated
that BMD was significantly lower in children with
congenital hypothyroidism [11]. Significant reduction
in BMD was also reported during a short period of
treatment with L-T4 [12]. Other researchers have
found no significant change in BMD in congenital
hypothyroidism treated with L-T4 [13, 14].
In this study we aim to detect the effects of 
L-T4 treatment on bone mineral and body compo  -
sition in paediatric cases with hypothyroidism.
Material and methods
Thirty-five patients suffering from hypothy  -
roidism (25 females and 10 males) were included in
this study. Their mean age was 11.57 ±5.06 years.
They are all under L-T4 replacement therapy in
a dose ranging from 75 µg to 200 µg per day 
(1-8 µg/kg/day). Mean follow-up thyroid stimulating
hormone (TSH) was 4.48 ±3.37 µU/ml where
minimum TSH level was 0.2 µU/ml. Mean serum
free T4 ranged from 1.1 pg/ml to 9.9 pg/ml. All
patients in their regular follow-up are doing well
and their growth parameters are completely
satisfactory under their L-T4 dose of replacement
therapy. They are all free from diseases other than
hypothyroidism. Twenty-six age- and sex-matched
healthy children served as controls. 
Again we divided cases depending on age and
period of treatment into three groups: group 1, of
which the period of treatment with L-T4 is less than
10 years and patients showed no signs of puberty;
group 2 where the period of treatment with L-T4 is
more than 10 years and patients showed no signs
of puberty; and group 3 where the period of
treatment with L-T4 is more than 10 years and
patients showed pubertal changes either completed
or started.
For all patients and controls BMD in g/cm2 and
bone mineral content (BMC) in g of the lumbar
spine and the left proximal femur (if unaffected by
disease, otherwise the right proximal femur) were
measured by dual energy X-ray absorptiometry
(DXA) using the Norland XR 46. The mean BMD
values of the second, third and fourth lumbar
vertebrae (lumbar spine BMD) and of the femoral
neck of the proximal femur (femoral neck BMD)
were used in the present analysis. Z score > –1 was
considered normal, Z score between –1 and –2.5
was considered osteopenia and Z score = –2.5 was
considered osteoporosis. Body composition was also
studied for all by DXA.
Serum levels of calcium, phosphorus, osteocalcin
as a bone formation marker [15], osteoprotegerin
(OPG) as an indictor of osteoclast activity [16] and
urinary deoxypyridinoline (DPD) as a bone collagen
breakdown marker [17] were assessed for all
patients and controls.
The study was approved by the ethical
committee of the National Research Centre as part
of a project concerning early detection of
osteopenia and osteoporosis in Egyptian children.
All patients or their parents gave written informed
consent after full discussion about the whole
procedures.
Laboratory methods
A 10 ml fasting venous blood sample was taken
from each subject in the study. The serum was
separated by centrifugation and stored at –20°C for
the determination of: serum calcium, phosphorus,
osteocalcin, calcitonin, OPG, free T4 and TSH.
Random urine samples were also taken from each
subject in the study and stored at –20°C for
determination of DPD. 
Serum calcium and phosphorus were assayed
using an Olympus autoanalyser (AU 400).
Quantitative measurements of FT4 and TSH in
serum were made using an Immulite analyser. Kits
were supplied from Siemens Medical Diagnostics,
cat. no. LKF41 and LKRT1 respectively. 
Quantitative assays by enzyme-linked immuno  -
sorbent assay (ELISA) using solid phase amplified
sensitivity immunoassays were used to determine
the following parameters: osteocalcin (kit supplied
from Bio Source Europe S.A., cat. no. KAP1381); OPG
(kit supplied from Bio Vendor Laboratory Medicine,
Inc., cat. no. RD 194003200); calcitonin (kit supplied
from Diagnostic Systems Laboratories, Inc., cat. no.
DSL–10-7700); and DPD (kit supplied from METRA,
Quidel Corporation worldwide headquarters, 10165
McKellar Court, San Diego, CA 92121 USA).
To detect the possible effects of the different
periods of treatment on bone tissue and body
composition cases were divided into 3 groups:
group 1 where the period of treatment with L-T4
was less than 10 years and no signs of puberty had
appeared in any of the patients; group 2 where the
period of treatment was more than 10 years and
patients did not show any signs of puberty either;
and group 3 for patients treated for more than 
10 years and showing pubertal changes either
completed or started. Each group was compared
with age-, sex- and pubertal stage-matched controls.
Statistical analysis
The statistical package SPSS version 15 was used
for statistical analysis. Data were presented as
means ± standard deviation. Independent sampleArch Med Sci 3, June / 2010 409
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t-test was used to compare between cases and
controls and between the different groups. Pearson
correlation was used to correlate multiple variants.
A p-value of less than 0.05 was considered
statistically significant. 
Results
No significant differences were detected
between cases and controls in weight, height and
BMI. Table I shows the results of the bone study by
DXA where no significant results were detected
between cases and controls in different Z scores,
total BMD in g and BMC in g/cm2. Table II shows
the laboratory results where no significant
differences were found between cases and controls.
The calcitonin hormonal study for all the patients
gave results within the normal ranges for patients
under L-T4 replacement therapy.
Table III shows the comparison between cases
and controls in body composition where total fat is
slightly lower and lean body mass slightly higher in
cases than controls. However, both fail to show this
difference at a significant level.
Positive correlations were detected between
BMD, BMC and both the age of the patients and
their period of treatment with L-T4. Positive
correlations were also detected between BMD,
BMC, lean body mass, total fat and abdominal fat.
The highest correlations in BMD and BMC were
detected with total lean mass.
Further correlations between BMD, BMC,
Z scores and dose of L-T4, and levels of TSH and
FT4 in serum were insignificant.
In our study we did not observe a significant
difference between male and female cases in BMD,
BMC and Z scores. Body composition studies
showed a significant difference in gender regarding
BMI (males = 16.80 ±2.49 and females = 21.10 ± 5.20,
p = 0.02) and total body fat (males = 6.34 ±5.23 and
females = 14.61 ±9.17, p = 0.01). Lean body mass
showed insignificant differences between them
(males = 22.97 ±11.96 and females = 26.80 ±10.32,
p = 0.35).
Data from the different periods of treatment in the
three divided groups are shown in Tables IV-VI. Again
no significant differences between cases and controls
were found. A significant difference was detected only
in total body fat, it being significantly lower in 
L-thyroxin treated hypothyroid pubertal children than
their age- and sex-matched controls (Table VI).
Cases Controls Value of p 95% Confidence interval of the difference
Z-s FEMUR –0.167 ±0.579 –0.210 ±0.530 0.781 –0.263 0.486
Z-s LUMBAR –0.197 ±0.656 –0.331 ±0.751 0.187 –0.241  0.508
BMD [g/cm2] 0.712 ±0.152 0.6831 ±0.0997 0.406 –0.399 0.097
BMC [g] 1532.26 ±694.54 1364.462 ±485.935 0.296 –150.74 488.332
Results are shown as means ± standard deviations, Zs – Z score, BMD – bone mineral density in g/cm2, BMC – bone mineral content in g
Table I. DXA bone study data
Cases Controls Value of p 95% Confidence interval of the difference
Osteocalcin [ng/ml] 38.250 ±19.317 49.644 ±34.151 0.186 –2.8509 5.7218
Osteoprotegerin [pmol/l] 2.878 ±0.925 3.500 ±1.552 0.161 –1.5051 0.2617
DPD [mmol/mmol creatinine] 47.781 ±25.454 60.830 ±33.632 0.706 –31.832 5.7334
Calcium [mg/dl] 9.77 ±0.80 9.75 ±0.50  0.922 –0.4840 0.5332
Phosphorous [mg/dl] 4.78 ±0.74 4.71 ±0.91 0.803 –0.5139 0.6953
Results are shown as means ± standard deviations
Table II. Laboratory bone study
Cases Controls Value of p 95% Confidence interval of the difference
Total fat [kg] 12.25 ±8.10 14.45 ±13.15 0.441 –7.8727 3.4772
Abd. fat [kg] 2.01 ±1.77 2.11 ±2.43 0.830 –1.0417 0.8396
Lean mass [kg] 25.71 ±10.78 21.96 ±7.83 0.138 –1.2426 8.7424
Results are shown as means ± standard deviations
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Distribution N Mean Standard deviation Value of p 95% Confidence interval of the difference
Age [years]
Case l 14 6.286 2.643
0.190 –3.219 0.679
Cont l 9 7.556 1.130
BMI [kg/m2]
Case l 14 17.002 3.409
0.295 –1.262 3.962
Cont l 9 15.651 1.950
Z-score Case l 14 –0.243 0.649
0.903 –0.615 0.546
FEMUR Cont l 7 –0.209 0.474
Z-score Case l 14 –0.139 0.823
0.897 –0.693 0.786
LUMBAR Cont l 7 –0.186 0.615
Fat total [kg]
Case l 14 7.354 7.632
0.239 –2.275 8.625
Cont l 9 4.179 2.033
BMD [g/cm2]
Case l 14 0.581 0.068
0.163 –0.094 0.017
Cont l 9 0.620 0.053
BMC [g]
Case l 14 880.142 324.058
0.443 –336.334 152.400
Cont l 9 972.111 167.079
Lean total Case l 14 15.175 5.695
0.231 –6.823 1.741
[kg] Cont l 9 17.716 2.874
Case l – cases treated for less than 10 years with no signs of puberty yet, cont l – age- and sex-matched controls, BMI – body mass index, 
BMD – bone mineral density, BMC – bone mineral content
Table IV. Group 1 (period of treatment with L-T4 is less than 10 years and patients showed no signs of puberty)
Distribution N Mean Standard deviation Value of p 95% Confidence interval of the difference
Age [years]
Case m 7 12.00 0.816
0.71 –0.798 1.131
Cont m 6 11.83 0.75277
BMI [kg/m2]
Case m 7 20.46 5.988 0.47 –12.183 6.074
Cont m 6 23.52 8.901
Z-score Case m 7 –0.35 0.339
0.70 –0.876 0.609
FEMUR Cont m 6 –0.22 0.819
Z-score Case m 7 –0.64 0.305
0.34 –0.856 0.323
LUMBAR Cont m 6 –0.37 0.631
Fat total [kg]
Case m 7 13.22 9.255
0.20 –23.843 5.710
Cont m 6 22.28 14.751
BMD [g/cm2]
Case m 7 0.67 0.068
0.56 –0.134 0.076
Cont m 6 0.70 0.104
BMC [g]
Case m 7 1495.28 322.041
0.59 –656.94 396.84
Cont m 6 1625.33 531.856
Lean total  Case m 7 27.62 5.451
0.41 –6.019 13.66
[kg] Cont m 6 23.80 10.319
Case m – cases treated for 10 years or more with no signs of puberty yet, cont m – age- and sex-matched controls, BMI – body mass index, 
BMD – bone mineral density, BMC – bone mineral content
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Discussion
Thyroid hormone replacement has been used for
more than 100 years in the treatment of
hypothyroidism. Effects of L-T4 treatment on bone
mineralization of children are of great concern. Our
data showed no significant deteriorating effects on
BMD and BMC during the course of treatment with
L-T4. We also did not find any significant differences
in laboratory bone turnover markers such as
osteocalcin, calcitonin, OPG, DPD, calcium and
phosphorus between cases and controls.
The results of Ribot et al., in 1990, suggest that
in the case of primary hypothyroidism even
appropriate thyroid replacement therapy could lead
during the first year of treatment to a significant
reduction in vertebral and femoral BMD [12].
Demartini et al., in 2007, challenged the previously
published results in the literature showing that
hypothyroid children and adolescents with
congenital hypothyroidism had a significant
decrease in BMD compared to age- and sex-
matched controls [11]. 
Our data are in accordance with Salerno et al.,
2004, who concluded that prolonged treatment for
congenital hypothyroidism does not affect bone
tissue for 17 years of treatment [14]. In 1999
another study in children treated with L-T4 showed
that BMD at both the femur neck and lumbar spine
was not significantly different from that of the
control group. It also showed that osteocalcin and
calcitonin levels were not significantly different [13].
In a study with L-T4 replacement for eight years, in
children with congenital hypothyroidism, including
BMD, osteocalcin and urinary DPD, similar results
to this study were obtained [18]. Kooh et al., in 1997,
indicated that even large doses of LT-4 therapy for
congenital hypothyroidism do not cause osteopenia
in childhood [19].
Saggese et al., in 1996, examined adolescent girls
only and concluded that long-term L-T4 therapy in
adolescent girls has no adverse effect on BMD or
bone turnover and peak bone mass is not impaired
[20]. Our results showed no gender differences in
bone metabolism during treatment with L-T4 in
hypothyroids.
In a recent animal study TSH prevented bone
loss and restored bone mass in rats through both
anti-resorptive and anabolic effects on bone
remodelling [21]. Adverse effects of thyroxin such
as osteopenia are considerably more common when
serum thyrotrophin has been suppressed. Thus,
avoidance of dosages that cause thyrotrophin
suppression, when not clinically indicated, is the
primary approach to management of these adverse
effects [22, 23]. 
It was revealed that BMC and BMD values
intensively increase with age [24]. The positive
Distribution N Mean Standard  Standard error  Value of p 95% Confidence interval 
deviation mean of the difference
Age [years]
Case p 14 16.643 1.336 0.357
0.288 –0.577 1.863
Cont p 13 16.00 1.732 0.480
BMI [kg/m2]
Case p 14 22.462 4.477 1.196
0.113 –10.748 1.248
Cont p 9 27.211 6.780 3.390
Z-score Case p 14 0.003 0.587 0.156
0.222 –0.185 0.756
FEMUR Cont p 11 –0.281 0.533 0.160
Z-score Case p 14 –0.038 0.515 0.137
0.980 –0.378 0.367
LUMBAR Cont p 10 –0.030 0.282 0.089
Fat total [kg]
Case p 14 16.668 8.163 2.181
0.005 –17.267 –3.34
Cont p 12 26.973 9.037 2.608
BMD [g/cm2]
Case p 14 0.859 0.105 0.028
0.843 –0.090 0.074
Cont p 13 0.867 0.102 0.028
BMC [g]
Case p 14 2202.85 407.110 108.805
0.429 –200.03 455.89
Cont p 13 2074.92 420.180 116.537
Lean total  Case p 14 35.285 6.107 1.632
0.094 –0.958 10.46
[kg] Cont p 13 30.532 8.010 2.221
Case p – cases treated for 10 years or more with signs of puberty, Cont p – age- and sex-matched controls, BMI – body mass index, BMD – bone
mineral density, BMC – bone mineral content
Table VI. Group 3 (Period of treatment with L-T4 is more than 10 years and patients showed pubertal changes either
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correlation detected in our study between period
of treatment and both BMC and BMD is probably
related to the change of age, as the same positive
correlation was detected with age. Period of
treatment alone does not affect bone tissue
metabolism. Our three groups divided based on the
different periods of treatment showed no significant
differences in comparison to the age-, sex- and
pubertal stage-matched controls. 
Longer period of treatment in group 2 and group
3 showed better results in body composition, which
appeared as a slight decrease in fat and increase
in lean mass. However, body composition does not
alter with treatment with L-T4 in our study and no
significant changes in BMI, body fat and total lean
mass were detected in comparison with controls
except in pubertal children in group 3 where
a significant decrease in total body fat was detected
in treated cases. Similar results were obtained by
Brunova et al. in 2007, as they concluded that long-
term treatment of hypothyroidism did not lead to
weight loss or body composition changes [25].
Similar results were also reported by Lomenick 
et al. in 2008 [26]. Normal physiological differences
between males and females in body composition
did not alter either. 
The correlations detected in our study
concerning body composition are in accordance
with other studies in normal children and
adolescents. The correlations between BMI and
both BMD and BMC found in this study agree with
Lim et al., 2004 [27] and Leonard et al., 2004 [28].
Positive correlations between lean body mass and
both BMD and BMC have been documented by
many investigators. They all agree that it is the
most important related factor determining bone
mineralization in males and females [27, 29-31].
Positive correlations of BMD and BMC with total fat
and regional fat have also been detected by other
researchers [32, 33]. However, many of them
concluded that it is a better predictor of bone mass
in females [27, 34].
In conclusion, proper controlled replacement
therapy with L-T4 in hypothyroid children and
adolescents does not affect the BMD, BMC and
body composition or alter their normal age-and sex-
related physiological changes.
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